Stéphane Verdood

Biotechnological Enzymatic Catalyse NV develops, produces and commercializes enzymatic systems for food preservation. It engages in the research, development and manufacturing of antimicrobial products for food safety. The firm's solutions are designed for use in the following: dairy products, fruit and vegetable juices, sauces and dressings and liquid egg products. The company was founded in 1992 and is headquartered in Ghent, Belgium.

Fast Forward Pharmaceuticals BV develops novel disease-modifying therapeutics for the treatment of inflammatory and autoimmune diseases. It is developing an anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The company was founded by Louis Boon in October 2010 and is headquartered in Utrecht, Netherlands.

Part of Ernst & Young Global Ltd., Arthur Andersen /Belgium/ is a Belgian company that provides accounting services. The company is located in Belgium. The company was founded by Stéphane Verdood. Arthur Andersen /Belgium was acquired by Deloitte & Touche LLP from Arthur Andersen LLP on April 18, 2002.

Major SAS is engaged in the manufactures and retails clothes for children. It's products include shirts, pants, shoes, T-shirts, pyjamas, frocks, overalls, pullovers, coats, and bathing slips. The company was founded by Paul Zemmour in 1987 and is headquartered in Montreuil, France.

Part of Vesalius Biocapital Partners SARL, Vesalius Biocapital I Investments SA SICAR is a venture capital fund. The company is based in Luxembourg, Luxembourg.

Vesalius Biocapital I SA Sicar focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project.

Vesalius Biocapital Arkiv NV focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. Vesalius Biocapital Arkiv is part of the ARKImedes project which, is organized and/or managed by Participatiemaatschapij Vlaanderen NV.

Vesalius Biocapital II Arkiv NV focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. Vesalius Biocapital Arkiv is part of the ARKImedes project, which is organized and/or managed by Participatiemaatschapij Vlaanderen NV.

Part of Calliditas Therapeutics AB, Genkyotex Innovation SAS engages in research and development of biotechnology. The company is based in Saint Julien-en-Genevois, France.

Vesalius Biocapital II SA Sicar focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project.

Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland.

Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands.